[Nature Biomedical Engineering] Researchers engineered a hydrogel-based system for in situ Treg activation at injury sites through the controlled release of AS2863619, a cyclin-dependent kinase inhibitor.

[Alex’s Lemonade Stand Foundation for Childhood Cancer] Alex’s Lemonade Stand Foundation has funded 12 Innovation Grants to help researchers pursue bold ideas that could change the future of childhood cancer. Across these 12 projects, researchers are exploring new ways to overcome treatment resistance, detect disease earlier, and uncover vulnerabilities that could lead to new therapies.

[Anixa Biosciences, Inc. (BioSpace)] Anixa Biosciences, Inc. announced that it has completed dosing of the fifth cohort in its ongoing Phase I, dose-escalating, clinical trial evaluating its novel FSHR-targeted CAR-T therapy for recurrent ovarian cancer.

[Cancer Cell] The authors summarize the clinical lessons learned from the now substantial experience with commercial CAR T cells and clinical trials and discuss three waves shaping next-generation development

[Cellular & Molecular Immunology] To identify intrinsic persistence regulators in a TCR-based context, researchers performed an in vivo CRISPR activation screen in synthetic T cell receptor and antigen receptor T cells and identified the noncanonical NF-κB axis, with RELB as the top hit.

[Cell Stem Cell] Scientists developed PrimeCAR, a two-day manufacturing strategy combining low-intensity anti-CD3 priming with IL-7 and IL-21. Functionally, PrimeCAR cells demonstrated enhanced expansion, persistence, and durable antitumor activity in xenograft models.

[Nature Biotechnology] The authors developed NK cell-targeted LNPs (NtLNPs) using engineered biparatopic NK cell ligands to drive receptor-specific uptake and mRNA delivery. Systemic delivery of'CAR mRNA using NtLNPs generates CAR NK cells in vivo.

[JCI Insight] Scientists identified B7-H3 as a favorable target antigen for CAR T cell therapy of glioblastoma (GMB) and developed a B7-H3 targeting CAR T cell. Using orthotopic xenograft models of GBM, they show that a single intravenous administration of this B7-H3 targeted CAR confers tumor control, and long-term survival.

[Journal for Immunotherapy of Cancer] Investigators compared conventional CAR-T cells, systemic T cell engagers, TCE-secreting (STAb)-T cells, and dual-targeting CAR–STAb-T cells in immunocompetent mouse models of high-grade glioma.

[Annual Review of Medicine] The authors summarizes the biological rationale, clinical evidence, safety considerations, and resistance mechanisms of T cell receptor–engineered T cell therapy in solid tumors and discusses future directions to optimize their therapeutic potential.

[Blood] Through single cell RNA-sequencing of tumors at the time of progression from CART19, investigators showed that a subset of tumor contain clonally expanded and proliferating populations of CART19 cells that acquire transcriptional features of dysfunction, suggestive of ongoing tumor cell engagement and chronic stimulation.

[Nature Medicine] Investigators analyzed the phenotypic attributes of the anti-CD19 CAR T therapy axicabtagene ciloleucel (axi-cel) from 580 patients with non-Hodgkin lymphoma across multiple clinical trials with long-term follow-up. A high proportion of naive-like T cells was the most significant feature associated with prolonged progression-free survival.